Efalizumab
drugOn this page
Also known as ANTI-CD11AHU-1124HU1124Raptiva
Summary
Efalizumab (CHEMBL1201575) is an approved antibody (ATC L04AG02) targeting ITGAL; indicated across 10 conditions including psoriasis and sjogren syndrome.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- ATC class: L04AG02
- Targets: 1 (ITGAL)
- Indications: 10 conditions
- Clinical trials: 37
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201575 |
| Name | Efalizumab |
| Type | Antibody |
| Max phase | 4 |
| ATC | L04AG02 |
Also known as: ANTI-CD11A, Efalizumab, HU-1124, HU1124, Raptiva, EFALIZUMAB
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| ITGAL | integrin, alpha L subunit (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) | Binding | 11.4 | 0.2% | P20701 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): ITGAL.
Top Reactome pathways
14 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Hemostasis | 1 | ITGAL |
| Adaptive Immune System | 1 | ITGAL |
| Extracellular matrix organization | 1 | ITGAL |
| Innate Immune System | 1 | ITGAL |
| Immune System | 1 | ITGAL |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 1 | ITGAL |
| Cell surface interactions at the vascular wall | 1 | ITGAL |
| Generic Transcription Pathway | 1 | ITGAL |
| Integrin cell surface interactions | 1 | ITGAL |
| Neutrophil degranulation | 1 | ITGAL |
| RNA Polymerase II Transcription | 1 | ITGAL |
| Gene expression (Transcription) | 1 | ITGAL |
| Transcriptional regulation by RUNX3 | 1 | ITGAL |
| RUNX3 Regulates Immune Response and Cell Migration | 1 | ITGAL |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell | 1 |
| phagocytosis | 1 |
| inflammatory response | 1 |
| cell adhesion | 1 |
| heterophilic cell-cell adhesion | 1 |
| leukocyte cell-cell adhesion | 1 |
| cell-matrix adhesion | 1 |
| signal transduction | 1 |
| integrin-mediated signaling pathway | 1 |
| memory T cell extravasation | 1 |
| receptor clustering | 1 |
| cell-cell adhesion | 1 |
| T cell activation | 1 |
Indications & clinical
Indications
10 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| psoriasis | 4 | MONDO:0005083 | EFO:0000676 |
| Sjogren syndrome | 2 | MONDO:0010030 | EFO:0000699 |
| rheumatoid arthritis | 2 | MONDO:0008383 | EFO:0000685 |
| type 1 diabetes mellitus | 2 | MONDO:0005147 | MONDO:0005147 |
| alopecia | 2 | MONDO:0004907 | MONDO:0019080 |
| immune system disorder | 1 | MONDO:0005046 | EFO:0000540 |
| age-related macular degeneration | 1 | MONDO:0005150 | EFO:0001365 |
| psoriatic arthritis | 1 | MONDO:0011849 | EFO:0003778 |
| hidradenitis suppurativa | 1 | MONDO:0006559 | EFO:1000710 |
| chronic kidney disease | 1 | MONDO:0005300 | MONDO:0024327 |
Clinical trials
Total trials: 37.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 7 |
| PHASE3 | 7 |
| PHASE2 | 7 |
| PHASE1 | 7 |
| PHASE1/PHASE2 | 5 |
| Not specified | 3 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00096980 | PHASE4 | COMPLETED | A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies |
| NCT00287118 | PHASE4 | COMPLETED | A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis |
| NCT00302445 | PHASE4 | COMPLETED | A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis |
| NCT00312026 | PHASE4 | COMPLETED | A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet |
| NCT00336973 | PHASE4 | COMPLETED | A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent |
| NCT00669214 | PHASE4 | COMPLETED | A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp |
| NCT00972543 | PHASE4 | TERMINATED | Raptiva in Palm and Sole Psoriasis |
| NCT00096603 | PHASE3 | COMPLETED | A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g |
| NCT00109252 | PHASE3 | COMPLETED | A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g |
| NCT00109317 | PHASE3 | COMPLETED | A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy |
| NCT00115076 | PHASE3 | COMPLETED | Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis |
| NCT00256139 | PHASE3 | COMPLETED | CLEAR Study: Clinical Experience Acquired With Raptiva Study |
| NCT00338143 | PHASE3 | COMPLETED | A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies |
| NCT00442650 | PHASE3 | COMPLETED | Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis |
| NCT00729768 | PHASE2/PHASE3 | WITHDRAWN | A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation |
| NCT00034203 | PHASE2 | COMPLETED | Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis. |
| NCT00146003 | PHASE2 | COMPLETED | Efalizumab for Eczema |
| NCT00276250 | PHASE2 | COMPLETED | Islet Transplantation Using Abatacept |
| NCT00308204 | PHASE2 | WITHDRAWN | Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva |
| NCT00344448 | PHASE2 | TERMINATED | Pilot Study of Raptiva to Treat Sjogren’s Syndrome |
| NCT00368654 | PHASE1/PHASE2 | COMPLETED | Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy |
| NCT00472082 | PHASE1/PHASE2 | TERMINATED | Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients |
| NCT00501709 | PHASE1/PHASE2 | COMPLETED | Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus |
| NCT00672204 | PHASE1/PHASE2 | TERMINATED | Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes |
| NCT00737763 | PHASE2 | WITHDRAWN | Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab |
| NCT00746980 | PHASE2 | WITHDRAWN | Efalizumab in the Treatment of Alopecia, Phase II |
| NCT00777400 | PHASE1/PHASE2 | WITHDRAWN | Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells |
| NCT00051662 | PHASE1 | COMPLETED | Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis |
| NCT00134134 | PHASE1 | COMPLETED | Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa |
| NCT00226057 | PHASE1 | COMPLETED | Efalizumab for Moderate to Severe Atopic Dermatitis |
| NCT00280826 | PHASE1 | COMPLETED | Efalizumab to Treat Uveitis |
| NCT00382512 | PHASE1 | COMPLETED | A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis |
| NCT00676559 | PHASE1 | WITHDRAWN | Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study |
| NCT00726466 | PHASE1 | WITHDRAWN | Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration |
| NCT00133107 | Not specified | COMPLETED | Safety and Effectiveness of Efalizumab to Treat Oral Lichen Planus |
| NCT00184366 | Not specified | TERMINATED | Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis |
| NCT00489216 | Not specified | TERMINATED | Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
4 molecules share ≥1 primary target. Top 4 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| LIFITEGRAST | ChEMBL + PubChem | Phase 4 (approved) | ITGAL |
| LOVASTATIN | ChEMBL + PubChem | Phase 4 (approved) | ITGAL |
| Dexamethasone | PubChem | Approved | ITGAL |
| Tirofiban | PubChem | Approved | ITGAL |
Related Atlas pages
- Genes: ITGAL
- Diseases: psoriasis
- Drugs: Lifitegrast, Lovastatin, Dexamethasone, Tirofiban